2004
DOI: 10.1080/01443610400008024
|View full text |Cite
|
Sign up to set email alerts
|

Outcome of the first 220 cases of endometrial balloon ablation using Cavaterm™plus

Abstract: The objective of this prospective study was to evaluate the effectiveness of day-case Cavaterm plus thermal balloon endometrial ablation in the treatment of therapy-resistant menorrhagia. The study included 220 patients with a mean age of 41 years, mean parity of 2.1 and mean duration of menorrhagia of 3.2 years. A 6-mm diameter Cavaterm plus catheter with a silicone balloon at its tip was used. The ablation time was 10 minutes at a temperature of 78 degrees C. No procedure-related operative or immediate posto… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
5
0

Year Published

2005
2005
2018
2018

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 12 publications
(7 citation statements)
references
References 34 publications
2
5
0
Order By: Relevance
“…The success rate of the present study (88.5%) was comparable with other studies which have used this method for destroying the endometrium [14][15][16][17][18][19][20][21][22][23][24][25] (Table 3). Also, our results indicated a higher rate of success in comparison to to other methods for the ablation of the endometrium [9,10,26,29,30].…”
Section: Discussionsupporting
confidence: 79%
“…The success rate of the present study (88.5%) was comparable with other studies which have used this method for destroying the endometrium [14][15][16][17][18][19][20][21][22][23][24][25] (Table 3). Also, our results indicated a higher rate of success in comparison to to other methods for the ablation of the endometrium [9,10,26,29,30].…”
Section: Discussionsupporting
confidence: 79%
“…As we had no information about follicle‐stimulating hormone levels, we did not know whether the possible amenorrhoea was due to the procedure or menopause. In addition, the device used was unknown in most cases, but according to previous studies, there is no evidence of the superiority of one device over another (6), (9), (17).…”
Section: Discussionmentioning
confidence: 99%
“…The largest study to date reported on 220 patients treated with the Cavaterm Plus device, with follow-up for an average of 19 months. 75 The satisfaction rate at the end of the follow-up interval was 83%. Another study of 50 patients followed for an average of 14 months (range, 6 to 24 mo) reported a short-term success rate of 96%, with 68% of patients developing amenorrhea, 24% with spotting, 4% eumenorrhea, and 4% failures.…”
Section: Cavatermmentioning
confidence: 98%